ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer

Non‐small cell lung cancer (NSCLC) patients harboring EGFR sensitive mutations may benefit from treatment with EGFR TKIs. Osimertinib, which is an irreversible third‐generation EGFR TKI, has demonstrated a convincing efficacy, irrespective of whether it is used in first‐ or second‐line treatment. Th...

Full description

Bibliographic Details
Main Authors: Helei Hou, Dantong Sun, Chuantao Zhang, Dong Liu, Xiaochun Zhang
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Thoracic Cancer
Subjects:
Acquired resistance
ALK rearrangement
EGFR mutation
NSCLC
osimertinib
Online Access:https://doi.org/10.1111/1759-7714.13817

Internet

https://doi.org/10.1111/1759-7714.13817

Similar Items